Why Intensity Therapeutics, Inc.’s (INTS) Stock Is Down 37.51%
As of Friday, October 31, Intensity Therapeutics, Inc.’s INTS share price has dipped by 37.51%, which has investors questioning if this is right time to buy.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.
Commentary & Analysis
Is Intensity Therapeutics Inc (INTS) Stock a Good Investment?
Learn more about Intensity Therapeutics Inc's (INTS) stock grades for Growth and determine whether this Biotechnology & Medical Research stock meets your investment needs.Grace Malone
Financial Summary
| Share Statistics | INTS | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $11.2 | $252.6 | 7% |
|
| Shares Out (Mil) | 2.5 | 52.3 | 9% |
|
| Institutional Ownership | 59.6% | 92.1% | 39% |
|
| Float (Mil) | 2.5 | 40.2 | 6% |
|
| Beta | 3.06 | 0.95 | 98% |
|
| Avg Daily Volume (000s) | 25 | 455 | 22% |
|
| Price Change (52-week) |
(45.6%) | 52.9% | 17% |
|
| Growth | INTS | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.6% | na |
|
| Net Income (5yr) | (14.1%) | (9.9%) | 26% |
|
| EPS (5yr) | 28.0% | 16.0% | 78 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (29.8%) | (15.6%) | 19% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 3 | 3 | 2 | |
| Current EPS | ($0.773) | ($3.133) | ($2.700) | |
| Month Ago EPS | ($0.773) | ($3.133) | ($2.700) | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 0 | 0 | 0 | |
| Three Months Ago EPS | ($0.917) | ($3.603) | ($2.950) | |
| Year/Year Chg | (19.6%) | (63.4%) | (49.9%) | |
| Financials | INTS | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $38 | na |
|
| Net Income (TTM) (Mil) | ($11) | ($43) | 29% |
|
| EPS (TTM) | ($5.817) | ($1.600) | 7% |
|
| Operating Cash Flow (TTM) (Mil) | ($9) | ($31) | 20% |
|
| Net Cash Flow (TTM) (Mil) | na | $5 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $5 | 10% |
|
| Enterprise Value (Q1) (Mil) | $-0 | $180 | 3% |
|
| Valuation | INTS | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.06 | 2.56 | 25% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | INTS | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 63.8% | na |
|
| Net Margin | na | (67.3%) | na |
|
| ROA | (139.3%) | (49.8%) | 4% |
|
| ROE | (207.4%) | (55.5%) | 4% |
|
| Liabilities to Assets | 18.8% | 30.3% | 12% |
|
| F-Score | 3 | 3 | 19% |
|
Intensity Therapeutics, Inc. did not pass any screens on 7/31/2026.
